FAB.L实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (1 Jul 2024 @ 16:29):
Our systems believe the stock currently is undervalued by 0.00% compare to its pairs and should correct upwards.

Stats
今日成交量	25 225
平均成交量	946 307
市值	2.96M
EPS	£-0.0292 ( Q2 \| 2023-09-30 )
下一个收益日期	( £0 ) 2024-09-27
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-0.340 (Sector) 0 (Industry) 0
ATR14	£0.0830 (2.68%)

AMYT.L -11.73%

APH.L -0.26%

AVCT.L -2.70%

AZN.L -0.37%

BMK.L 2.34%

BVXP.L -2.16%

C4XD.L 27.32%

CIR.L 0.00%

CLIN.L 0.11%

DEST.L -0.80%

DPH.L 0.05%

EAH.L 3.20%

ERGO.L 0.15%

ETX.L -6.74%

EVG.L 2.25%

FAB.L -1.59%

FARN.L -5.98%

FUM.L 0.27%

GDR.L 4.84%

GNS.L 1.44%

GSK.L -0.52%

HCM.L -0.36%

HEMO.L 1.82%

HIK.L -0.58%

IMM.L -1.15%

INDV.L 0.08%

IXI.L -5.25%

MTPH.L 1 794.74%

MXCT.L -2.17%

N4P.L -4.71%

NCYT.L -2.42%

NFX.L -5.00%

OBD.L 3.33%

OKYO.L -24.32%

ONC.L 0.45%

OPTI.L -3.63%

OVB.L -2.22%

OXB.L 2.53%

PRM.L -4.82%

PRTC.L 0.55%

PYC.L -6.25%

REDX.L 31.58%

RENE.L -2.17%

SAR.L 5.84%

SCLP.L -1.86%

SLN.L -0.93%

SNG.L 4.05%

STX.L 2.70%

TILS.L 8.33%

TRX.L -2.06%

VAL.L 0.00%

VEC.L 0.00%

相关性 (AI algo v.1.1b): Undervalued: 0.00% £3.10 paired level. (算法实时跟踪最相关股票的变化并提供即时更新)

Fusion Antibodies PLC 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Fusion Antibodies PLC 财务报表

Annual	2022
营收:	£2.90M
毛利润:	£202 000 (6.96 %)
EPS:	£-0.0998

FY	2022
营收:	£2.90M
毛利润:	£202 000 (6.96 %)
EPS:	£-0.0998

FY	2022
营收:	£4.80M
毛利润:	£2.47M (51.39 %)
EPS:	£-0.0463

FY	2021
营收:	£4.17M
毛利润:	£2.02M (48.60 %)
EPS:	£-0.131

Financial Reports:

No articles found.

Fusion Antibodies PLC Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Fusion Antibodies PLC

Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. It offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. The company serves pharmaceutical, biotech, and diagnostic companies. It has a collaboration partnership with Celonic AG. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.